Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 1

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 1
---
 Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☐

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to such Section 8(a), may determine.

<div align='center'>EXPLANATORY NOTE</div>

This registration statement of Tiziana Life Sciences Ltd. (the “Registrant”) contains:

| ● | a base prospectus which                                                                                                                 
 covers the offering, issuance and sale by the Registrant of the securities identified above from time to time in one or more offerings, 
 which together shall have an aggregate offering price not to exceed $250,000,000; and                                                   |
| ● | a sales agreement prospectus                                                                                                            
 covering the offering, issuance and sale of up to $100,000,000 of common shares that may be issued and sold under the Open Market       
 Sale Agreement℠, dated October 25, 2024 (the “Sales Agreement”), between the Registrant and Jefferies LLC, or Jefferies.                |

The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus